Last updated: March 7, 2026
What is the Medication Associated with NDC 00088-2161?
NDC 00088-2161 corresponds to Humulin R U-100 (insulin human, recombinant), manufactured by Eli Lilly. It is a rapid-acting insulin used for blood glucose control in diabetes mellitus.
Market Size and Demand Dynamics
Global Insulin Market Overview
- The insulin market was valued at approximately USD 25 billion in 2022.
- Compound annual growth rate (CAGR): 8.2% (2023-2028).
- Drivers: Rising diabetes prevalence, increasing adoption of basal-bolus regimens, and expanding healthcare coverage.
U.S. Insulin Market Breakdown
- Estimated market size: USD 16 billion in 2022.
- Number of insulin users: About 8 million Americans with diagnosed diabetes (CDC, 2022).
- Market share of human insulins (like Humulin R): Approximately 15–20%; the remaining dominated by analog insulins.
Competitive Landscape
- Major insulin products include analogs (e.g., Novo Nordisk’s Novolin, Eli Lilly’s Humulin; Sanofi’s Lantus).
- Biosimilars entering markets have begun to affect pricing and market share, particularly in Europe and the U.S.
Price Projections and Trends
Current Pricing Data
- Wholesale acquisition cost (WAC): Approximate list price for a 10 mL vial of Humulin R is USD 130–150.
- Reimbursement rates vary, with average retail prices around USD 70–90 per 10 mL vial after discounts or insurance adjustments.
Historical Pricing Trends
- The price of human insulin has been relatively stable over the last five years, with annual increases around 2–3% due to inflation and manufacturing costs.
- Biosimilar introductions in some markets led to minor price reductions, but overall price stability persists due to insulin’s essential nature and limited substitutes.
Price Projection Outlook (Next 5 Years)
- Conservative Scenario: Prices increase 2% annually, reaching approximately USD 160–180 per vial by 2028.
- Aggressive Biosimilar Impact: Prices could decrease by 10–15% in some regions if biosimilars penetrate sufficiently, leading to prices around USD 110–130 per vial.
- Regulatory and Policy Factors: Price controls or reimbursement reforms could suppress prices further.
Factors Influencing Future Pricing
- Market Competition: Increased biosimilar approvals (e.g., Eli Lilly’s unauthorized biosimilar for Humulin in Europe) may pressure prices.
- Manufacturing Costs: Technological advances could lower production expense, impacting retail prices.
- Reimbursement Policies: Medicaid, Medicare, and private payers' negotiations influence retail costs.
- Patent Status: Eli Lilly's patent exclusivity will expire in 2024, opening market space for biosimilars.
Key Market Challenges and Opportunities
Challenges
- Market saturation in developed regions limits growth.
- Biosimilar access and acceptance are uneven, especially in the U.S.
- Pricing pressures from healthcare payers and regulators.
Opportunities
- Expansion into emerging markets offers volume growth.
- Collaborations with pharmacy benefit managers (PBMs) could influence formulary placement.
- Development of combination insulin products enhances therapeutic options.
Summary
| Aspect |
Data Point |
| Current Market Size (US) |
USD 16 billion (2022) |
| Estimated Market Share (Humulin R) |
15–20% of insulin market |
| Current Price (per 10 mL vial) |
USD 130–150 (list price) |
| 5-year Price Projection |
USD 110–180 (depending on biosimilar entry and policy shifts) |
| CAGR (2023–2028) |
8.2% for insulin market overall |
Key Takeaways
- NDC 00088-2161 (Humulin R) remains a stable, but eventually declining, segment within the highly competitive insulin market.
- Biosimilar market entry likely to moderate prices in the future.
- Price increases are expected to stay within 2–3% annually, but policy and market dynamics could alter this trajectory.
- Growth opportunities reside chiefly in emerging markets and therapeutic innovation.
FAQs
What is the primary use for Humulin R?
It treats diabetes mellitus by controlling blood glucose levels, used mainly in basal-bolus insulin therapy.
Will biosimilars significantly reduce Humulin R prices?
Potentially yes; biosimilars could bring prices down 10–15% if supported by regulatory approval and market acceptance.
Are there patent expirations affecting this drug?
Yes, Eli Lilly’s patent protections are set to expire in 2024, opening the market broadly to biosimilars.
How does Humulin R compare to analog insulins?
Humulin R, being human insulin, has a shorter duration and slower onset with less flexibility compared to analog insulins but is generally less expensive.
What market factors could influence insulin prices in the next five years?
Regulatory reforms, biosimilar competition, healthcare reimbursement policies, and technological advances in manufacturing.
References
- CDC. (2022). National Diabetes Statistics Report. Centers for Disease Control and Prevention.
- Grand View Research. (2023). Insulin Market Size, Share & Trends Analysis. https://www.grandviewresearch.com
- Eli Lilly and Company. (2022). Humulin R Product Monograph.
